Curium files IND application for prostate PET agent

By staff writers

August 24, 2021 -- Nuclear medicine firm Curium has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for its copper-64 (Cu-64) PSMA I&T diagnostic radiopharmaceutical.

Designed to detect and localize metastatic prostate cancer on PET exams, Cu-64 PSMA I&T binds to prostate-specific membrane antigen (PSMA), according to the vendor. The radiopharmaceutical would enable imaging sites in the U.S. to provide PSMA-based prostate cancer imaging without local cyclotron production or access to a nearby gallium generator, Curium said.

Copyright © 2021
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking